7 hasil untuk "1"
Menampilkan 1–7 · 0,33 detik · RSS
-
Artikel Jurnal Teks lengkap
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Antisense oligonucleotides (ASOs) are incredibly versatile molecules that can be designed to specifically target and modify RNA transcripts to slow down or halt rare genetic disease progression. They offer the potential to target groups of patients or can be tailored for individual cases…
-
Artikel Jurnal
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
AIM: To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. MATERIALS AND METHODS: with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose…
-
Artikel Jurnal Teks lengkap
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective
Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to…
Dari koleksi institusi
- Codification Of Statements On Auditing StandardsTo 1 Numbers · 1983 · Universitas Riau (UNRI)
- Keputusan-Keputusan Keuangan Perusahaan : teori dan hasil pengujian empirikNapa 1, Awat, MS.; Muljadi, Ps, MS. · 1989 · Universitas Riau (UNRI)
-
Artikel Jurnal Teks lengkap
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD…
-
Artikel Jurnal Teks lengkap
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
T cell subsets indicated that partially exhausted effector cells were associated with clinical response. Thus, this trial showed improvement in metabolic responses and delay of diabetes with immune therapy.
-
Artikel Jurnal Teks lengkap
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized…
-
Artikel Jurnal Teks lengkap
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021